Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes

Executive Summary

Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.


Related Content

Manufacturer Communications: Industry Seeks Single Evidentiary Standard
Off-Label Wish List: Industry Groups Want US FDA's Guidances To Do More
Off-Label Promotion: 'Safe Harbor' Preferable To Expansive Free Speech Rulings
Off-Label Communications: Industry, FDA Debate Role Of Peer Review
Pharma's Medical Liaisons: From KOLs To Outcomes And Virtual Options
Industry's Off-Label Hearing Priorities Taking Shape
Rx Economic Information-Sharing Concept Getting Renewed Push
US FDA Sets Goal For Biosimilar, Drug Promotion Guidances
HHS Price Forum: Surprisingly Good Context For Pharma Ideas For Regulatory Changes
Medicare Oncology Payment Program Could Pressure Part D Prices, Industry Says





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts